2009 Hauptstadtkongress debates affordability of innovation for the German healthcare system

  • Posted on 29.05.2009

2009 Hauptstadtkongress debates affordability of innovation for the German healthcare system

grossienmark

Mark Grossien

Former Director Communications & External Affairs at Eucomed

hc-inno

Is innovation still affordable with increasingly strained healthcare budgets? How can medical innovations continued to be financed? Panelist of the round table of distinguished speakers Member of the European Parliament Jorgo Chatzimarkakis made a statement which nicely complements the study released by AdvaMed only 2 days ago. He said that innovation does not increase costs although many people tend to believe they do.
Chatzimarkakis continued to point out that Germany’s HTA agency IGWiQ and the way it currently operates does not support innovation uptake as it only looks at the cost impact of the technology today rather than looking at the ultimate benefit they might yield to society at a later stage. To me, it’s refreshing to see that not all policy makers are members of the large group of skeptics of the benefit and value of investing in innovations.

– Mark Grossien, Director of Communications & External Affairs, Eucomed

The comments are closed.